Evidence mapPaperPMID 40502812Full record

ReviewMedComm2025

Resveratrol: Molecular Mechanisms, Health Benefits, and Potential Adverse Effects.

Zhuo-Qun Ren, Sheng-Yuan Zheng, Zhengcheng Sun, Yan Luo, Yu-Tong Wang, Ping Yi, Yu-Sheng Li, Cheng Huang, Wen-Feng Xiao

Abstract readReview
In one paragraph

Review in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Rab27: Molecular switch of tumor exosome secretion (Review).International journal of molecular medicine · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhuo-Qun RenDepartment of Orthopedics Xiangya Hospital Central South University Changsha Hunan China.
Sheng-Yuan ZhengDepartment of Orthopedics Xiangya Hospital Central South University Changsha Hunan China.
Zhengcheng SunDepartment of Orthopedics Xiangya Hospital Central South University Changsha Hunan China.
Yan LuoDepartment of Orthopedics Xiangya Hospital Central South University Changsha Hunan China.
Yu-Tong WangDepartment of Orthopedics Xiangya Hospital Central South University Changsha Hunan China.
Ping YiDepartment of Orthopaedic Surgery China-Japan Friendship Hospital Beijing China.
Yu-Sheng LiDepartment of Orthopedics Xiangya Hospital Central South University Changsha Hunan China.
Cheng HuangDepartment of Orthopaedic Surgery China-Japan Friendship Hospital Beijing China.
Wen-Feng XiaoDepartment of Orthopedics Xiangya Hospital Central South University Changsha Hunan China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resveratrol (RES), a naturally occurring polyphenolic compound, has garnered significant attention due to its diverse biological activities, which include anti-inflammatory, antioxidant, and antiaging properties. This review synthesizes current evidence concerning the molecular mechanisms, therapeutic efficacy, and safety profile of RES across a variety of pathologies, with an emphasis on the latest research conducted in recent years. Mechanistically, RES is known to modulate critical signaling pathways such as the activation of sirtuin 1. These actions collectively contribute to the attenuation of oxidative stress, regulation of apoptosis, and promotion of autophagy. Preclinical studies have demonstrated the potential of RES in the mitigation of degenerative musculoskeletal disorders, cardiovascular diseases, cancer progression, and neurological diseases. Given the low bioavailability of RES and the potential for adverse reactions in clinical applications, we summarize and discuss its safety profile while outlining future research directions. This review underscores the therapeutic versatility of RES while advocating for rigorous pharmacokinetic optimization, standardized dosing protocols, and large-scale randomized controlled trials to validate its efficacy and safety in human populations.

Indexed as

agingcancerpathogenesispotential adverse effectsresveratroltherapeutic mechanisms

Identifiers

PMID40502812
PMCPMC12152427

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.